Search PubMed⌕ Search

Biomedical subjects

A Serafini

Publications and source records attributed to A Serafini.

28 records · Page 2Linked to original sources
PubMed1972

Comparison of fluorescent antibody induced by rubella virus in vaccinee and convalescent individuals.

Specific rubella antibody detectable by indirect immunofluorescence developed in response to immunization with attenuated rubella vaccine, HPV-77, DK-12. Fluorescent antibody (FA) was found when vaccinee sera were reacted with antigens synthesized in three different acutely infected continuous cell lines: BHK-21, LLCMK-2, and RK-13. FA titers were high, and they correlated with antibody titers obtained by hemagglutination-inhibition tests. Levels of FA in vaccinated individuals were slightly lower than those found in persons recovered from natural rubella infections. Rubella FA persists a long time in convalescent individuals and appears to be maintained for at least 19 months in vaccinees.

Animals↗
PubMedDate not supplied

Theoretical analysis of the two-coil method for measuring fluid flow using nuclear magnetic resonance.

A theoretical study of the application of pulsed nuclear magnetic resonance (NMR) to the measurement of fluid flow has been made. Calculations of detector signal line shapes, for a two-coil NMR laboratory experiment, were performed using a computer to determine the appropriate choice of flow signature. Results of calculations are presented showing the sensitivity of the method to various experimental parameters. The position of the received peak signal, in time, was found to correlate directly with mean flow velocity. However, the shape of the received signal was observed to depend markedly upon the state of flow, i.e., laminar, turbulent (plug). Hence, accurate determinations of flow required a knowledge of flow type. The theoretical calculations provided a better understanding of the potential of NMR for measuring fluid or blood flow.

Blood Flow Velocity↗
PubMedDate not supplied

Review of tests for monitoring doxorubicin-induced cardiomyopathy.

The objective of this review is to make physicians aware of new radionuclide methods to detect cardiac effects of chemotherapeutic drugs. This knowledge is important because of the limitations of the physical examination and the electrocardiogram for detecting early reversible cardiac damage. Presently left ventricular ejection fraction (LVEF) is routinely used to screen for cardiotoxicity. Since LVEF obtained by radionuclide angiocardiography is more accurate than the LVEF estimated by echocardiography, serial radionuclide LVEF monitoring is most commonly used to monitor cardiotoxicity. Diastolic measurements of left ventricular function (such as peak filling rate) are now being added to routine LVEF measurements to enhance standard radionuclide evaluation. This screening test should be done prior to beginning therapy and at appropriate points based on the baseline study, therapy scheme and the patient's clinical status. At some centers, exercise LVEF methods are being used to determine if cardiac reserve is adequate for the patient to tolerate additional chemotherapy when cardiac injury may be present. Previously, endomyocardial biopsy was needed to detect and confirm early anthracycline cardiotoxicity. This invasive test may be replaced by a new noninvasive in vivo method using radioactive monoclonal antibodies against cardiac muscle (indium-111-antimyosin). Because cardiac failure has been associated with adrenergic neuron injury, it has been proposed that radioactive methyliodobenzylguanine may detect the adrenergic abnormality which may predict future development of congestive heart failure or sudden death months after therapy is discontinued. Advantages and disadvantages of these methods in evaluating cardiotoxicity, and an algorithm to optimally monitor antitumor therapy-induced cardiomyopathy are discussed.

Antibiotics, Antineoplastic↗
PubMedDate not supplied

Momento mori.

Explore the source record for details and available documents.

Brain Death↗